<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04955275</url>
  </required_header>
  <id_info>
    <org_study_id>BHS-1660</org_study_id>
    <nct_id>NCT04955275</nct_id>
  </id_info>
  <brief_title>The Efficacy of a Remote Cognitive Remediation Therapy (CRT) Program on Parkinson's Disease</brief_title>
  <official_title>The Efficacy of a Remote Cognitive Remediation Therapy (CRT) Program on Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Institute of Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose/Goal: To determine if a remote computerized cognitive remediation program (CRT) can&#xD;
      stabilize or improve cognitive functioning in a group of patients from the AHCC with&#xD;
      Parkinson's disease (PD) after three months of intervention.&#xD;
&#xD;
      Hypothesis: Patients with PD who present with current cognitive deficits will show&#xD;
      improvement in such deficits after three months of participation in a remotely supervised&#xD;
      structured Cognitive Remediation Therapy Program (CRT) compared to control subjects with PD&#xD;
      who receive treatment as usual.&#xD;
&#xD;
      Research design: Pilot study. Prospective randomized treatment and control comparison&#xD;
      pre-post study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 16, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Pre-Intervention</measure>
    <time_frame>Initially, before any intervention/start of study.</time_frame>
    <description>A brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Post-Intervention</measure>
    <time_frame>10 weeks after intervention/completion of the study.</time_frame>
    <description>A brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parkinson's Disease Questionnaire (PDQ-39) Pre-Intervention</measure>
    <time_frame>Initially, before any intervention/start of study.</time_frame>
    <description>A test that assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parkinson's Disease Questionnaire (PDQ-39) Post-Intervention</measure>
    <time_frame>10 weeks after intervention/completion of the study.</time_frame>
    <description>A test that assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montreal Cognitive Assessment (MOCA) Pre-Intervention Screening</measure>
    <time_frame>Initially, before any intervention/start of study.</time_frame>
    <description>A rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's Disease Patients receiving Cognitive Remediation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parkinson's Disease Subjects will undergo 10 weeks of Brain HQ training, 2 times a week an hour at a time. Also patients pre- and post-intervention RBANS and PDQ-39 scores.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson's Disease Patients not receiving Cognitive Remediation Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Parkinson's Disease Subjects will receive no intervention, but still undergo pre- and post-intervention RBANS and PDQ-39 scores.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Remediation Therapy Program (BrainHQ)</intervention_name>
    <description>Brain HQ games involving training cognitive abilities like memory and attention, made up of adapting tasks or creating our own.</description>
    <arm_group_label>Parkinson's Disease Patients receiving Cognitive Remediation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be currently enrolled in the Rock Steady Boxing Program at the Adele&#xD;
             Smithers Parkinson's Disease Center.&#xD;
&#xD;
          2. Subjects must be between 40 and 78 years old (including both ages) at the time of&#xD;
             study screening.&#xD;
&#xD;
          3. Subjects must have a diagnosis of Parkinson's disease by a physician.&#xD;
&#xD;
          4. Subjects must have a MOCA score of 20 or above.&#xD;
&#xD;
          5. Subjects must demonstrate adequate decisional capacity, in the judgment of the&#xD;
             consenting study staff member, to make a choice about participating in this research&#xD;
             study.&#xD;
&#xD;
          6. Subjects must have been clinically stable for 2 weeks prior to consent; in the&#xD;
             judgment of the Investigator.&#xD;
&#xD;
          7. Subjects must have the visual, auditory, and motor capacity to use the intervention in&#xD;
             the judgment of the Principal Investigator.&#xD;
&#xD;
          8. Subjects must be technologically capable of utilizing a computer and navigating&#xD;
             through the programs.&#xD;
&#xD;
          9. Subjects must be mechanically capable of utilizing a computer and computer mouse.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects should not be participating in a concurrent research study or other&#xD;
             interventional clinical trial 30 days prior to consenting.&#xD;
&#xD;
          2. Subjects should not have a history of mental retardation or pervasive developmental&#xD;
             disorder; or other co-morbid neurological disorder (e.g., epilepsy.)&#xD;
&#xD;
          3. Subject is unable to physically use a computer or a computer mouse.&#xD;
&#xD;
          4. Subject is unable to or refuses to give consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa Hoffman, PhD</last_name>
    <phone>5166861179</phone>
    <email>Lisa.Hoffman@nyit.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York Institute of Technology</name>
      <address>
        <city>Old Westbury</city>
        <state>New York</state>
        <zip>11568</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Hoffman, Ph. D.</last_name>
      <phone>516-686-1179</phone>
      <email>Lisa.Hoffman@nyit.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Hoffman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saeed Yasin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Volino</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Madison Baker</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Díez-Cirarda M, Ibarretxe-Bilbao N, Peña J, Ojeda N. Efficacy of cognitive rehabilitation in Parkinson's disease. Neural Regen Res. 2018 Feb;13(2):226-227. doi: 10.4103/1673-5374.226390.</citation>
    <PMID>29557365</PMID>
  </reference>
  <reference>
    <citation>Díez-Cirarda M, Ojeda N, Peña J, Cabrera-Zubizarreta A, Lucas-Jiménez O, Gómez-Esteban JC, Gómez-Beldarrain MÁ, Ibarretxe-Bilbao N. Increased brain connectivity and activation after cognitive rehabilitation in Parkinson's disease: a randomized controlled trial. Brain Imaging Behav. 2017 Dec;11(6):1640-1651. doi: 10.1007/s11682-016-9639-x.</citation>
    <PMID>27757820</PMID>
  </reference>
  <reference>
    <citation>Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014 Mar;275(3):214-28. doi: 10.1111/joim.12190.</citation>
    <PMID>24605806</PMID>
  </reference>
  <reference>
    <citation>Gough N, Brkan L, Subramaniam P, Chiuccariello L, De Petrillo A, Mulsant BH, Bowie CR, Rajji TK. Feasibility of remotely supervised transcranial direct current stimulation and cognitive remediation: A systematic review. PLoS One. 2020 Feb 24;15(2):e0223029. doi: 10.1371/journal.pone.0223029. eCollection 2020.</citation>
    <PMID>32092069</PMID>
  </reference>
  <reference>
    <citation>Milman U, Atias H, Weiss A, Mirelman A, Hausdorff JM. Can cognitive remediation improve mobility in patients with Parkinson's disease? Findings from a 12 week pilot study. J Parkinsons Dis. 2014;4(1):37-44. doi: 10.3233/JPD-130321.</citation>
    <PMID>24322063</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 3, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT04955275/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

